Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Hotchkis & Wiley Capital Management LLC

Key Points

• Hotchkis & Wiley Capital Management LLC increased its stake in Amphastar Pharmaceuticals by 13.7%, purchasing an additional 32,630 shares to hold a total of 270,150 shares valued at $7.8 million.
• Amphastar Pharmaceuticals' stock has a market capitalization of $1.42 billion, with a current PE ratio of 11.42 and trading near $30.50.
• Analysts have mixed ratings on Amphastar, with a current average price target of $31.50, reflecting two "Buy" ratings and two "Hold" ratings among research analysts.

Hotchkis & Wiley Capital Management LLC lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 13.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 270,150 shares of the company's stock after buying an additional 32,630 shares during the period. Hotchkis & Wiley Capital Management LLC owned approximately 0.57% of Amphastar Pharmaceuticals worth $7,832,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMPH. TD Asset Management Inc increased its holdings in shares of Amphastar Pharmaceuticals by 20.2% during the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after buying an additional 371,856 shares during the last quarter. Systematic Financial Management LP purchased a new position in Amphastar Pharmaceuticals in the 4th quarter valued at about $9,147,000. Royce & Associates LP boosted its position in Amphastar Pharmaceuticals by 2,684.3% in the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company's stock valued at $7,185,000 after buying an additional 238,956 shares during the last quarter. Boston Trust Walden Corp boosted its position in Amphastar Pharmaceuticals by 24.2% in the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock valued at $35,241,000 after buying an additional 236,704 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company's stock worth $36,632,000 after buying an additional 130,672 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on AMPH shares. JPMorgan Chase & Co. reissued a "neutral" rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research report on Friday, August 8th. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Bank of America upped their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research report on Tuesday. Finally, Needham & Company LLC raised shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price on the stock in a report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH traded up $0.39 during trading hours on Friday, reaching $30.65. The company's stock had a trading volume of 195,467 shares, compared to its average volume of 570,428. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The business has a 50-day simple moving average of $24.48 and a 200 day simple moving average of $25.80. Amphastar Pharmaceuticals, Inc. has a 52 week low of $20.39 and a 52 week high of $53.96. The stock has a market cap of $1.42 billion, a PE ratio of 11.48 and a beta of 0.76.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.